UBS Group’s PureTech Health PRTC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-20
| Closed | -$297 | – | 10906 |
|
|
2026
Q1 | $297 | Hold |
20
| – | – | ﹤0.01% | 9971 |
|
|
2025
Q4 | $334 | Hold |
20
| – | – | ﹤0.01% | 10025 |
|
|
2025
Q3 | $370 | Hold |
20
| – | – | ﹤0.01% | 9713 |
|
|
2025
Q2 | $345 | Hold |
20
| – | – | ﹤0.01% | 9862 |
|
|
2025
Q1 | $396 | Sell |
20
-1,883
| -99% | -$34.4K | ﹤0.01% | 9795 |
|
|
2024
Q4 | $35.1K | Buy |
1,903
+1,256
| +194% | +$26.3K | ﹤0.01% | 7513 |
|
|
2024
Q3 | $13.3K | Buy |
647
+296
| +84% | +$6.47K | ﹤0.01% | 7591 |
|
|
2024
Q2 | $8.78K | Buy |
351
+331
| +1,655% | +$9.27K | ﹤0.01% | 7780 |
|
|
2024
Q1 | $570 | Hold |
20
| – | – | ﹤0.01% | 8468 |
|
|
2023
Q4 | $564 | Sell |
20
-8
| -29% | -$163 | ﹤0.01% | 8587 |
|
|
2023
Q3 | $644 | Buy |
28
+8
| +40% | +$215 | ﹤0.01% | 8357 |
|
|
2023
Q2 | $570 | Sell |
20
-1
| -5% | -$28 | ﹤0.01% | 8176 |
|
|
2023
Q1 | $609 | Buy |
21
+1
| +5% | +$30 | ﹤0.01% | 8958 |
|
|
2022
Q4 | $638 | Hold |
20
| – | – | ﹤0.01% | 10112 |
|
|
2022
Q3 | $1K | Sell |
20
-349
| -95% | -$9.2K | ﹤0.01% | 10010 |
|
|
2022
Q2 | $7K | Buy |
369
+349
| +1,745% | +$8.01K | ﹤0.01% | 8517 |
|
|
2022
Q1 | $1K | Hold |
20
| – | – | ﹤0.01% | 9905 |
|
|
2021
Q4 | $1K | Hold |
20
| – | – | ﹤0.01% | 10017 |
|
|
2021
Q3 | $1K | Sell |
20
-43
| -68% | -$2.09K | ﹤0.01% | 9226 |
|
|
2021
Q2 | $3K | Sell |
63
-66
| -51% | -$3.55K | ﹤0.01% | 8833 |
|
|
2021
Q1 | $7K | Sell |
129
-96
| -43% | -$5.36K | ﹤0.01% | 8162 |
|
|
2020
Q4 | $12K | Buy |
+225
| New | +$9.99K | ﹤0.01% | 7350 |
|
UBS Group's PRTC Position: Q2 2026 in Review
UBS Group sold out of PureTech Health (PRTC) in Q2 2026, closing a stake of 20 shares — an estimated $297 sold.
UBS Group first reported a position in PRTC in Q4 2020 and held it in 22 quarters. The position peaked at $35.1K in Q4 2024. 0 funds tracked by Wall St. Rank hold PRTC as of Q2 2026.
- UBS Group reported no remaining PureTech Health position as of Q2 2026 after selling out during the quarter.
- UBS Group sold 20 PureTech Health shares in Q2 2026, an estimated $297.
- UBS Group first reported a position in PureTech Health in Q4 2020 and held it in 22 quarters.
- UBS Group's PureTech Health position peaked at $35.1K in Q4 2024.
- 0 funds tracked by Wall St. Rank held PureTech Health as of Q2 2026.
Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.